Table 5 Antimicrobial susceptibility of KP and antimicrobial therapy in patients with KP pneumonia alone and KP-pneumonia/KP-BSI
Bacteriology | Total (n = 409) | KP pneumonia alone (n = 274) | KP-pneumonia/KP-BSI (n = 135) | P-value |
|---|---|---|---|---|
Antimicrobial susceptibility, n (%) | ||||
 Amoxicillin-clavulanic acid | 223 (54.5%) | 203 (74.1%) | 20 (14.8%) | P < 0.01 |
 Amikacin | 315 (77%) | 244 (89.1%) | 71 (52.6%) | P < 0.01 |
 Aztreonam | 221 (54%) | 198 (82.3%) | 23 (17%) | P < 0.01 |
 Ceftazidime | 232 (56.7%) | 208 (76%) | 24 (17.8%) | P < 0.01 |
 Ciprofloxacin | 246 (60.1%) | 208 (75.9%) | 38 (28.1%) | P < 0.01 |
 Cefatriaxone | 206 (49.6%) | 189 (69%) | 17 (12.6%) | P < 0.01 |
 Cefoperazone -Sulbactam | 237 (57.9%) | 211 (77%) | 23 (17%) | P < 0.01 |
 Cefepime | 242 (59.2%) | 214 (78.1%) | 28 (20.7%) | P < 0.01 |
 Cefoxitin | 233 (57%) | 207 (75.5%) | 26 (19.3%) | P < 0.01 |
 Piperacillin-tazobactam | 237 (57.9%) | 208 (75.9%) | 26 (19.2%) | P < 0.01 |
 Levofloxacin | 252 (61.6%) | 213 (77.7%) | 34 (25.2%) | P < 0.01 |
 Imipenem | 238 (58.2%) | 211 (77%) | 27 (20%) | P < 0.01 |
 Meropenem | 240 (58.7%) | 214 (78.2%) | 26 (29.3%) | P < 0.01 |
 Tigecycline | 375 (91.7%) | 260 (94.9%) | 115 (85.2%) | P < 0.01 |
 Compound sulfamethoxazole | 113 (27.6%) | 42 (15.3%) | 71 (52.6%) | P < 0.01 |
 Appropriate antimicrobial therapy, n (%) | 288 (70.1%) | 227 (82.8%) | 61 (45.2%) | P < 0.01 |